HK1254362A1 - 用於治療認知損害的苯並二氮雜環庚三烯衍生物、組合物和方法 - Google Patents

用於治療認知損害的苯並二氮雜環庚三烯衍生物、組合物和方法

Info

Publication number
HK1254362A1
HK1254362A1 HK18113438.3A HK18113438A HK1254362A1 HK 1254362 A1 HK1254362 A1 HK 1254362A1 HK 18113438 A HK18113438 A HK 18113438A HK 1254362 A1 HK1254362 A1 HK 1254362A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
cognitive impairment
treating cognitive
benzodiazepine derivatives
Prior art date
Application number
HK18113438.3A
Other languages
English (en)
Inventor
B‧梅科嫩
J‧A‧布特拉
黃建星
Original Assignee
艾吉因生物股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 艾吉因生物股份有限公司 filed Critical 艾吉因生物股份有限公司
Publication of HK1254362A1 publication Critical patent/HK1254362A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
HK18113438.3A 2015-06-19 2018-10-19 用於治療認知損害的苯並二氮雜環庚三烯衍生物、組合物和方法 HK1254362A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562182336P 2015-06-19 2015-06-19
PCT/US2016/038224 WO2016205739A1 (en) 2015-06-19 2016-06-17 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Publications (1)

Publication Number Publication Date
HK1254362A1 true HK1254362A1 (zh) 2019-07-19

Family

ID=57546444

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113438.3A HK1254362A1 (zh) 2015-06-19 2018-10-19 用於治療認知損害的苯並二氮雜環庚三烯衍生物、組合物和方法

Country Status (13)

Country Link
US (3) US10815242B2 (zh)
EP (1) EP3310785A4 (zh)
JP (2) JP6987384B2 (zh)
CN (2) CN108026107B (zh)
AU (2) AU2016279052A1 (zh)
CA (1) CA2990004C (zh)
EA (1) EA036844B1 (zh)
HK (1) HK1254362A1 (zh)
IL (1) IL256354B (zh)
MA (1) MA42624A (zh)
MX (2) MX2017015752A (zh)
WO (1) WO2016205739A1 (zh)
ZA (1) ZA201800360B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN108026107B (zh) 2015-06-19 2021-07-30 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA3104478A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX2022007725A (es) * 2019-12-19 2022-07-19 Agenebio Inc Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo.
AU2021304355A1 (en) * 2020-07-10 2023-03-02 Agenebio, Inc. Polymorphs of a GABA
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
CH603545A5 (zh) 1972-04-20 1978-08-31 Merz & Co
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4816456A (en) 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
CA2000786C (en) 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
ATE94384T1 (de) 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
DE69021645T2 (de) 1989-05-19 1996-02-22 Hoechst Roussel Pharma N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
DE69131268T2 (de) 1990-09-21 1999-12-30 Rohm & Haas Dihydropyridazinone und Pyridazinone als Fungizide
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
EP0586551A1 (en) 1991-05-24 1994-03-16 E.I. Du Pont De Nemours And Company Arthropodicidal anilides
US5106856A (en) 1991-06-07 1992-04-21 Hoechst-Roussel Pharmaceuticals Inc. [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
TW201311B (zh) * 1991-06-17 1993-03-01 Hoffmann La Roche
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
CZ284633B6 (cs) 1994-03-02 1999-01-13 Akzo Nobel N. V. Farmaceutický prostředek a použití trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrolu pro výrobu farmaceutického prostředku
US6479523B1 (en) 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
WO1999025353A1 (en) 1997-11-13 1999-05-27 Merck Sharp & Dohme Limited Therapeutic uses of triazolo-pyridazine derivatives
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
JP2002529468A (ja) 1998-11-12 2002-09-10 メルク エンド カムパニー インコーポレーテッド ＧＡＢＡ−Ａα−５逆活性薬の治療性多形およびそのパモエート組成物
KR100694682B1 (ko) 1999-03-03 2007-03-13 에자이 알앤드디 매니지먼트 가부시키가이샤 4-치환 피페리딘 유도체 불화물
GB9911802D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9911803D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9911804D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9929569D0 (en) 1999-12-14 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US20020151591A1 (en) 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
TWI239333B (en) 2000-11-16 2005-09-11 Hoffmann La Roche Benzodiazepine derivatives as GABA A receptor modulators
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
CN1494422A (zh) 2001-03-01 2004-05-05 �Ʒ� Gabaa反相激动剂与烟碱受体不完全激动剂、雌激素、选择性雌激素调节剂、或维生素e联合用于认知障碍的用途
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
WO2003025122A2 (en) 2001-08-13 2003-03-27 University Of Kentucky Research Foundation Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
CA2473536A1 (en) 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
GB0218876D0 (en) 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
US20060235021A1 (en) 2002-08-13 2006-10-19 Wesley Blackaby Phenylpyridazine derivatives as ligands for gaba receptors
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
MXPA04006900A (es) 2002-10-24 2004-10-15 Merz Pharma Gmbh & Co Kgaa Politerapia que utiliza derivados de 1-aminociclohexano e inhibidores de acetilcolinesterasa.
US20040191803A1 (en) 2002-11-22 2004-09-30 Michela Gallagher Target for therapy of cognitive impairment
AR046601A1 (es) 2003-10-22 2005-12-14 Merz Pharma Gmbh & Co Kgaa Uso de derivados 1- aminociclohexano para modificar la deposicion de peptidos ab fibrosos en amiloidopatias
WO2006034465A1 (en) 2004-09-23 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of childhood behavioral disorders
EP1809297B1 (en) * 2004-10-12 2008-07-30 F. Hoffmann-Roche AG Imidazo[1,5a]triazolo[1,5d]benzodiazepine derivatives for the treatment of cognitive disorders
WO2006045430A1 (en) * 2004-10-20 2006-05-04 F. Hoffmann-La Roche Ag Imidazo-benzodiazepine derivatives
WO2006045429A1 (en) * 2004-10-20 2006-05-04 F. Hoffmann-La Roche Ag Halogen substituted benzodiazepine derivatives
BRPI0515800A (pt) 2004-12-14 2008-08-05 Hoffmann La Roche imidazo-benzodiazepinas tetracìclicas como moduladores de receptores de gaba
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US7595395B2 (en) 2005-05-16 2009-09-29 Wisys Technology Foundation Gabaergic agents to treat memory deficits
WO2007019312A2 (en) 2005-08-03 2007-02-15 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
US8510055B2 (en) 2005-08-03 2013-08-13 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
CN101287738B (zh) 2005-10-11 2011-08-10 弗·哈夫曼-拉罗切有限公司 咪唑并苯并二氮杂*衍生物
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010036553A1 (en) 2008-09-24 2010-04-01 E. I. Du Pont De Nemours And Company Fungicidal pyridazines
CN105309424B (zh) 2008-09-25 2022-09-02 维乌作物保护有限公司 生产聚合物纳米颗粒的方法和活性成分的制剂
JP2012524065A (ja) 2009-04-17 2012-10-11 ゼノポート，インコーポレーテッド ＧＡＢＡＢ受容体リガンドとしてのγ−アミノ酪酸誘導体
WO2011085406A1 (en) 2010-01-11 2011-07-14 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
EP2635277B1 (en) 2010-11-05 2018-12-19 F.Hoffmann-La Roche Ag Use of active pharmaceutical compounds for the treatment of central nervous system conditions
WO2012068161A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012068149A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Benzodiazepine derivatives, compositions and methods for treating cognitive impairment
JPWO2012161133A1 (ja) 2011-05-20 2014-07-31 日産化学工業株式会社 置換ピリダジン化合物及び農園芸用殺菌剤
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
AU2013312240A1 (en) 2012-09-10 2015-03-19 Ophirex Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN108026107B (zh) 2015-06-19 2021-07-30 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
CN108567787A (zh) 2017-03-10 2018-09-25 辛衍雪 一种治疗慢性阻塞性肺病的药物组合物
CA3104478A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Also Published As

Publication number Publication date
MX2020013374A (es) 2022-05-06
IL256354B (en) 2022-09-01
US11312721B2 (en) 2022-04-26
EP3310785A1 (en) 2018-04-25
CA2990004A1 (en) 2016-12-22
US20210009602A1 (en) 2021-01-14
MX2017015752A (es) 2018-04-13
CN113264939A (zh) 2021-08-17
EA201890090A1 (ru) 2018-09-28
EA036844B1 (ru) 2020-12-28
US10815242B2 (en) 2020-10-27
CN108026107B (zh) 2021-07-30
JP2018521034A (ja) 2018-08-02
US20190055258A1 (en) 2019-02-21
US20220274996A1 (en) 2022-09-01
ZA201800360B (en) 2023-03-29
CN108026107A (zh) 2018-05-11
IL256354A (en) 2018-02-28
EP3310785A4 (en) 2018-12-26
CA2990004C (en) 2024-04-23
WO2016205739A1 (en) 2016-12-22
AU2021200164A1 (en) 2021-03-18
JP6987384B2 (ja) 2021-12-22
AU2016279052A1 (en) 2018-02-15
MA42624A (fr) 2021-04-28
AU2021200164B2 (en) 2022-09-08
JP2021152071A (ja) 2021-09-30

Similar Documents

Publication Publication Date Title
IL267451A (en) Benzodiazepine derivatives, compounds, and methods for treating cognitive impairment
ZA201605027B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1254358A1 (zh) 用於治療突觸核蛋白病的藥劑、用途和方法
HK1254362A1 (zh) 用於治療認知損害的苯並二氮雜環庚三烯衍生物、組合物和方法
IL263224A (en) Methods and preparations for the treatment of cancer
HK1252797A1 (zh) 用於治療病理性鈣化病況的組合物和使用該組合物的方法
IL253979B (en) Methods, preparations and kits for cancer treatment
IL279530A (en) Benzodiazepine history, preparations, and methods for the treatment of cognitive disorder
HK1244217A1 (zh) 用於治療蛋白質病的方法
HK1261918A1 (zh) 預防和/或治療與衰老有關的認知障礙和神經炎症的方法
PL3261644T3 (pl) Kompozycje i sposoby leczenia degradacji siatkówki
SG11201700530PA (en) Agent for improving brain function and agent for preventing or treating cognitive impairment
PT3552017T (pt) Compostos úteis como inibidores de ripk1
IL271728A (en) Materials, uses and treatment methods
EP3386594A4 (en) COMPOSITIONS AND METHODS FOR TREATING MEDICATION RESISTANT MULTI-MEDIUM GLIOBLASTOMA
IL272246A (en) Preparations and methods for treating galactosemia
HK1211441A1 (zh) 用於治療、預防或者減輕神經炎症或者認知損傷的方法
HK1256541A1 (zh) 用於處理皮膚的方法和組合物
ZA201907283B (en) Compositions, devices and methods for treating autism
EP3244914A4 (en) Methods for treating tauopathy
EP3139744A4 (en) Methods and compositions for treating and preventing tinnitus
ZA201904328B (en) Composition, application thereof and treatment method
EP3334424A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALOPECIA
IL257433B (en) Combinations of lanvatinib, ifosfamide and etoposide for the treatment of tumors
EP3397271A4 (en) COMPOSITIONS AND METHOD FOR TREATING RETINOPATHY